← Back to Search

Stem Cell Transplantation

Haplo SCT for Acute Myeloid Leukemia

N/A
Waitlist Available
Research Sponsored by Jonas Mattsson
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years and 5 years
Awards & highlights

Study Summary

This trial is ongoing, but not yet recruiting patients.

Eligible Conditions
  • Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years and 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Intention to treat analysis of 2-year graft-vs.-host disease- and relapse-free survival
Secondary outcome measures
Acute graft.vs.-host disease
Bone Transplantation
Engraftment of neutrophil granulocytes
+12 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Haplo SCTExperimental Treatment1 Intervention
Allogeneic stem cell transplantation with a haplo-identical family donor graft.
Group II: URD SCTActive Control1 Intervention
Allogeneic stem cell transplantation with a matched unrelated donor graft.

Find a Location

Who is running the clinical trial?

Jonas MattssonLead Sponsor
Helsinki University Central HospitalOTHER
430 Previous Clinical Trials
579,261 Total Patients Enrolled
Sahlgrenska University Hospital, SwedenOTHER
417 Previous Clinical Trials
297,756 Total Patients Enrolled
~3 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top